Conceptus Announces FDA Approval to Remove Nickel Contraindication From the Essure Procedure Instructions

Conceptus, Inc. CPTS,developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, today announced that effective immediately, the U.S. Food and Drug Administration has approved the removal of the nickel hypersensitivity contraindication from the Essure procedure Instructions for Use.